Edition:
United States

Edwards Lifesciences Q1 Earnings Per Share $1.18


Tuesday, 23 Apr 2019 04:15pm EDT 

April 23 (Reuters) - Edwards Lifesciences Corp ::EDWARDS LIFESCIENCES REPORTS FIRST QUARTER RESULTS.Q1 ADJUSTED EARNINGS PER SHARE $1.32.Q1 EARNINGS PER SHARE $1.18.Q1 SALES $993 MILLION VERSUS REFINITIV IBES ESTIMATE OF $989.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $1.22 -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.RAISED ITS FULL YEAR 2019 ADJUSTED EARNINGS PER SHARE GUIDANCE TO $5.10 TO $5.35.2019 ADJUSTED EPS GUIDANCE RAISED TO $5.10 TO $5.35.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 TO $4.3 BILLION REMAINS UNCHANGED.FOR Q2 2019, COMPANY PROJECTS TOTAL SALES TO BE BETWEEN $1.02 BILLION AND $1.08 BILLION.FOR Q2 2019, COMPANY PROJECTS ADJUSTED EPS OF $1.27 TO $1.37. ADJUSTED EPS OF $1.27 TO $1.37..Q2 EARNINGS PER SHARE VIEW $1.33, REVENUE VIEW $1.04 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $4.14 BILLION -- REFINITIV IBES DATA.2019 SALES GUIDANCE FOR EDWARDS OF $3.9 BILLION TO $4.3 BILLION REMAINS UNCHANGED.EDWARDS LIFESCIENCES - FOR QUARTER, REPORTED TAVR SALES OF $598 MILLION, 8 PERCENT GROWTH RATE OVER Q1 LAST YEAR, OR 10 PERCENT ON AN UNDERLYING BASIS.EDWARDS LIFESCIENCES - DURING QUARTER, RECORDED A $24 MILLION CHARGE RELATED TO PREVIOUSLY ANNOUNCED ACQUISITION OF STRATEGIC TRANSCATHETER TECHNOLOGY.